M&A Deal Summary |
|
|---|---|
| Date | 2020-12-28 |
| Target | Rare Pediatric Disease Priority Review Voucher |
| Sector | Life Science |
| Buyer(s) | United Therapeutics |
| Sellers(s) | AbbVie |
| Deal Type | Divestiture |
| Deal Value | 105M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Medical Products |
| Employees | 950 |
| Revenue | 2.3B USD (2023) |
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics was founded in 1996 and is based in Silver Spring, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector (Life Science) | 1 of 2 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 3 of 4 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-08-30 |
SteadyMed
San Ramon, California, United States SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development-stage drug-device combination product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. SteadyMed has signed an exclusive license and supply agreement with Cardiome Pharma Corp. |
Buy | $216M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-10-30 |
Miromatrix
Eden Prairie, Minnesota, United States Miromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix Medical has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. Miromatrix was founded in 2009 and is headquartered in Eden Prairie, Minnesota. |
Buy | $91M |
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 50,000 |
| Revenue | 54.3B USD (2023) |
AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-15 |
Mavupharma
Kirkland, Washington, United States Mavupharma is a biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. Mavupharma was founded in 2016 and is based in Kirkland, Washington. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-03-01 |
Syndesi Therapeutics
Louvain-la-Neuve, Belgium Syndesi Therapeutics is a clinical-stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The company's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. It was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Syndesi Therapeutics was formed in 2017 and is based in Louvain-la-Neuve, Belgium. |
Buy | $1.0B |
